Caris Life Sciences (CAI) Cash & Equivalents (2024 - 2026)

Caris Life Sciences' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $821.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents changed N/A year-over-year to $821.1 million; the TTM figure through Mar 2026 stood at $821.1 million (changed N/A YoY), while the FY2025 annual figure was $797.8 million, up 1119.09% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $821.1 million, up from $797.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $821.1 million in Q1 2026, with the low at $65.4 million in Q4 2024.
• The 3-year median for Cash & Equivalents is $754.7 million (2025), against an average of $631.9 million.
• Peak annual rise in Cash & Equivalents reached 1119.09% in 2025, while the deepest fall reached 1119.09% in 2025.
• Caris Life Sciences' Cash & Equivalents stood at $65.4 million in 2024, then soared by 1119.09% to $797.8 million in 2025, then grew by 2.93% to $821.1 million in 2026.
• Business Quant data shows CAI's Cash & Equivalents at $821.1 million in Q1 2026, $797.8 million in Q4 2025, and $754.7 million in Q3 2025.